[The pharmacokinetic and pharmacodynamic characteristics of foridon during interaction with the metabolic oxidation inhibitor dopegit]

Abstract

The paper deals with some aspects of the effects produced by dopegite on the pharmacokinetics and pharmacodynamics of foridone from a group of calcium antagonists. Nineteen patients with essential hypertension received a single doses of foridone of 40 mg, then its course therapy in a dose of 90 mg/day for 2 weeks, then it was supplemented with dopegite in a dose of 750 mg/day for 2 weeks too. Supplementation of dopegite caused statistically significant changes as higher plasma concentrations of foridone and increased concentration-time curve areas, decreased total peripheral resistance and regional, and a lower spasm index. Dopegite can be used to enhance the antihypertensive effect of foridone.